Notably, in NSCLC patients MEK5-ERK5 signalling is often upregulated and correlates with poor patient survival (Sanchez-Fdez et al, 2021), thus these patients are expected to exhibit inherent FAK inhibitor resistance, providing additional rationale for the use of MEK5 or ERK5 inhibitors in the clinic. This evidence concerns the gene PTK2 and non-small cell lung carcinoma.